Provided herein are compositions and methods related to a solid dosage form comprising an absorption enhancer. The composition enhances the mucosal penetration and absorption of active ingredients.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Provided is an administration device having a novel structure that enables anyone to uniformly jet and stably administer a substance to be administered such as a powdery drug. This device is a single-use type administration device 10 for administering a preset amount of a substance to be administered, such as a powdery drug, into the nasal cavity, etc. The administration device 10 is equipped with: a pump member 20 which has a squeezed shape as a whole and deforms when pressed to reduce the internal volume thereof; and a cylindrical guide member 30 which is positioned inside the pump member 20 and guides the deformed part of the pump member 20. The pump member 20 is in a shape having a tapered large-diameter part 21 and a tapered small-diameter part 22 which has a smaller diameter than the large-diameter part 21. Between the large-diameter part 21 and the small-diameter part 22, a step 23, wherein the degree of squeezing changes in the course of the squeezed shape, may be formed.
A61M 16/20 - Valves specially adapted to medical respiratory devices
B05B 11/06 - Gas or vapour producing the flow, e.g. from a compressible bulb or air pump
B05B 11/10 - Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
An adjuvant composition containing an adjuvant and a complex including microparticles of a biodegradable polymer and/or cyclodextrin, wherein the adjuvant is incorporated into the microparticles of the biodegradable polymer and/or is clathrated in the cyclodextrin.
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
[Problem] To provide a urine scattering prevention device which does not give off a foul smell even when used, and which is easy to replace. [Solution] A urine scattering prevention device 1 includes a urine receiving portion 5 disposed in a urinal 3, and a leg portion 7 which supports the urine receiving portion 5 vertically upward.
An object of the present invention is to provide a powder formulation for intranasal administration, which efficiently exhibits a medicinal effect, and the like. The object can be achieved by a powder formulation for intranasal administration comprising composite particles in which an active ingredient and a water-insoluble polysaccharide are cohered to each other.
A device according to one aspect of the present invention is an intranasal powdered medicine dispensing device (10) for dispensing a predetermined dose of a powdered medicine into a nasal cavity. The device includes a nozzle member (20) that includes a filling space (22) for a powdered medicine (M) and an ejection opening (26) for the powdered medicine (M), a closing member that closes the ejection opening (26), a sealing member (40) that seals an opening (24) of the filling space (22), an injection pump member (50) that sends out air, as the injection pump member contracts, to eject the powdered medicine from the ejection opening (26), a puncturing member (60) that moves, as the injection pump member (50) contracts, and forms a hole by puncturing in the sealing member (40) while moving, and a guide member (70) that restricts the puncturing member (60) from moving in a direction perpendicular to the direction of the movement thereof.
[Problem] To provide a urine scattering prevention device which does not give off a foul smell even when used, and which is easy to replace. [Solution] A urine scattering prevention device 1 includes a urine receiving portion 5 disposed in a urinal 3, and a leg portion 7 which supports the urine receiving portion 5 vertically upward.
An object of the present invention is to provide a powder preparation and the like suitable for selective administration to an olfactory region and the like. The object is achieved by a powder preparation for selectively administering an active ingredient to an olfactory region in a nasal cavity, the powder preparation comprising the active ingredient and having a bulk density of 0.1 to 0.5 g/cm3 and a Hausner ratio of 1.6 to 2.4.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/515 - Barbituric acidsDerivatives thereof, e.g. sodium pentobarbital
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
11.
MASS SPECTROMETRY METHOD USING CHROMATOGRAPHY-MASS SPECTROMETRY DEVICE
[Problem] To provide a mass spectrometry method that uses a chromatography-mass spectrometry device, wherein mass spectrometry can be performed with a convenient method at low cost. [Solution] A mass spectrometry method for a target object, using a chromatography-mass spectrometry device that includes, in order, a chromatograph, an ionization unit, a first mass separation unit, a collision cell, a second mass separation unit, and an ion detection unit, wherein an ion pair agent and Hünig's base are added to a mobile phase of the chromatograph, and the absolute value of an applied voltage of the collision cell is 20V to 250V.
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
[Problem] To provide a mass spectrometry method that uses a chromatography-mass spectrometry device, wherein mass spectrometry can be performed with a convenient method at low cost. [Solution] A mass spectrometry method for a target object, using a chromatography-mass spectrometry device that includes, in order, a chromatograph, an ionization unit, a first mass separation unit, a collision cell, a second mass separation unit, and an ion detection unit, wherein an ion pair agent and Hünig's base are added to a mobile phase of the chromatograph, and the absolute value of an applied voltage of the collision cell is 20V to 250V.
The present invention addresses the problem of providing a powder preparation for transnasal administration, the preparation efficiently demonstrating drug efficacy. The problem can be solved by a powder preparation for transnasal administration, containing composite particles in which an effective component and a water-insoluble polysaccharide adhere to each other.
The present invention addresses the problem of providing a powder preparation for transnasal administration, the preparation efficiently demonstrating drug efficacy. The problem can be solved by a powder preparation for transnasal administration, containing composite particles in which an effective component and a water-insoluble polysaccharide adhere to each other.
a) in the medicine container (21), and that is opened when administering medicine. The nozzled cartridge (20) is detachably mountable to a sprayer (30) when administering medicine.
To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. This micro-encapsulated aquaculture feed includes: an oil phase 11 having an oil-soluble nutrient component; a water phase 13 which is present inside the oil phase 11, and which includes a water-soluble nutrient component; and a film 15 which includes the oil phase 11 and the water phase 13. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.
A device according to an embodiment of the present invention is a nasal cavity powder medicine dispensing device (10) for dispensing a predetermined dose of a powder medicine into a nasal cavity. This device comprises a nozzle member (20) having a powder medicine (M) filling space (22) and a powder medicine (M) spouting opening (26), an opening member for opening the spouting opening (26), a seal member (40) for sealing an opening (24) of the filling space (22), a jetting pump member (50) for delivering air in accordance with a constricting action and causing the powder medicine to be spouted from the spouting opening (26), a perforating member (60) which moves in accordance with the constricting action of the jetting pump member (50) and forms a hole in the seal member (40) in the course of said movement, and a guide member (70) for restricting movement in the direction perpendicular to the direction of movement of the perforating member (60).
[Problem] To enable a person intended by a chairperson to be effectively determined as a speaker by matching the hand-raising of the speaker and an indicating direction of the chairperson, and turning ON only a microphone of the matched speaker. [Solution] Provided is a conference support system including: a plurality of voice input means which receive voices as an input; a plurality of ON/OFF control means which control the plurality of voice input means to be respectively turned ON/OFF and which respectively correspond to the plurality of voice input means; a hand-raising recognition means which recognizes hand-raising positions of participants, which respectively correspond to the plurality of voice input means; a designated direction recognition means which recognizes a direction designated by a specified person; and a speaker determination means which turns ON an ON/OFF control means for a voice input means that corresponds to a participant, when the hand-raising position of the participant, which is recognized by the hand-raising recognition means, matches the direction designated by the specified person, which is recognized by the designated direction recognition means.
[Problem] To provide: a feed for fish, the feed making it possible to suppress contamination into farming water or a water vessel wall surface without incurring a loss of palatability of a paste-form feed or a microparticulate feed; a method for producing the feed; and a method for farming fish in which the feed is used. [Solution] A feed for fish, the feed including: one or more main nutrients from among egg components, animal proteins, vegetable proteins, and marine-based components; and a flocculation-promoting substance.
A23K 40/10 - Shaping or working-up of animal feeding-stuffs by agglomerationShaping or working-up of animal feeding-stuffs by granulation, e.g. making powders
A23K 10/20 - Animal feeding-stuffs from material of animal origin
A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
The present invention addresses the problem of providing: a powdery preparation suitable for the selective administration to an olfactory region or the like; and others. The problem can be solved by a powdery preparation which contains an active ingredient and can be used for the selective administration of the active ingredient to an olfactory region in the nasal cavity, wherein the bulk density of the powdery preparation is 0.1 to 0.5 g/cm3 and the Hausner ratio of the powdery preparation is 1.6 to 2.4.
The present invention addresses the problem of providing: a powdery preparation suitable for the selective administration to an olfactory region or the like; and others. The problem can be solved by a powdery preparation which contains an active ingredient and can be used for the selective administration of the active ingredient to an olfactory region in the nasal cavity, wherein the bulk density of the powdery preparation is 0.1 to 0.5 g/cm3 and the Hausner ratio of the powdery preparation is 1.6 to 2.4.
AnguilliformesAnguilliformesAnguilliformesAnguilliformesAnguilliformesAnguilliformesAnguilliformesAnguilliformesAnguilliformesAnguilliformes larvae are reared in an environment at a salt concentration of 10-28‰ inclusive for at least a half of the second stage.
[Problem] To provide an enclosure that can be easily cleaned. [Solution] A fish-breeding enclosure including: a frame 3 constituting the sides of a cuboid; a first net 11 covering a right side surface 5, a bottom surface 7, and a left side surface 9 of the frame 3; a first net feeder 19 for feeding the first net 11 and a second net 17 that covers a front surface 13, the bottom surface 7, and a rear surface 15 of the frame 3; and a second net feeder 21 for feeding the second net 17. When the first net 11 or the second net 17 is renewed, the first net 11 or the second net 17 is drawn out from the first net feeder 19 or the second net feeder 21, respectively.
The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices, wherein the device comprises, a nozzle having a reservoir disposed within the nozzle, a valve at least partially fit into the reservoir, a retainer that is hollow and holds the valve, and a manual air pump operably linked to an upstream end of the nozzle and a downstream end of the retainer, wherein the valve has one or more contacting points with the retainer, and when the manual air pump is activated, said valve is lifted by the retainer and contacts the nozzle.
A61M 16/20 - Valves specially adapted to medical respiratory devices
B05B 11/10 - Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
27.
MEDICINE STORAGE CARTRIDGE WITH NOZZLE, SPRAYER THEREFOR, AND POWDERED MEDICINE DISPENSING DEVICE FOR NASAL CAVITY
In one aspect of the present invention, this medicine storage cartridge (20) with a nozzle is provided with: a medicine container (21) filled with a predetermined amount of a powdered medicine; a nozzle part (22) that is formed in the medicine container (21) and sprays the powdered medicine; a closing member (24) for closing an opening (22a) of the nozzle part (22); and a valve member (25) that functions as a stopper for closing another opening (23a) of the medicine container (21) and opens when the medicine is administered. The medicine storage cartridge (20) can be detachably attached to a sprayer (30) when the medicine is administered.
In one aspect of the present invention, this medicine storage cartridge (20) with a nozzle is provided with: a medicine container (21) filled with a predetermined amount of a powdered medicine; a nozzle part (22) that is formed in the medicine container (21) and sprays the powdered medicine; a closing member (24) for closing an opening (22a) of the nozzle part (22); and a valve member (25) that functions as a stopper for closing another opening (23a) of the medicine container (21) and opens when the medicine is administered. The medicine storage cartridge (20) can be detachably attached to a sprayer (30) when the medicine is administered.
Provided herein are vaccine compositions for example in a dry powder form for intranasal delivery, and their preparation methods. Also provided are methods of using vaccine compositions, for example in stimulating mucosal or systemic immune responses by delivering the vaccine compositions intranasally.
[Problem] To provide an aquarium with which it is possible to effectively cultivate fish. [Solution] A loop-type aquarium 1 has a first circular aquarium section 10, a second circular aquarium section 20, and a connecting section 30 that connects the aquarium sections 10 and 20. The connecting section 30 includes a first connecting flow channel 31 that connects a first end part 11 of the first circular aquarium section 10 with a first end part 21 of the second circular aquarium section 20, and a second connecting flow channel 32 that connects a second end part 12 of the first circular aquarium section 10 with a second end part 21 of the second circular aquarium section 20, the second connecting flow channel 32 being located under the first connecting flow channel 31.
[Problem] To provide breeding water for anguilliformes, and a method for rearing anguilliformes using the breeding water, in order to artificially control the transformation of glass eels and the like and produce glass eels and the like in the same size and form with a shorter period until birth. [Solution] Anguilliformes breeding water containing a thyroid hormone such as thyroxine, and a method for rearing anguilliformes including a step for administering a thyroid hormone such as thyroxine, wherein the amount of the thyroid hormone to be administered changes as the anguilliforme fingerling changes from a transformation start phase (stage 1) to a transformation final phase (stage 2), and the amount of the thyroid hormone to be administered in the transformation final phase (stage 2) is less than the amount of the thyroid hormone to be administered in the transformation start phase (stage 1).
[Problem] To provide a method for producing brassieres that can prevent sagging of breasts, achieve effortless bust uplift, and immobilize the breasts when prone. [Solution] A brassiere production method comprising a step for determining the shape of a region that comprises a breast (15) of a subject (11) when a nipple (13) of the subject (11) is turned vertically downward. An example of the state in which a nipple (13) is turned vertically downward is a state in which the subject is immobilized on a loading table (21) and, compared to the subject's nipple (13), the subject's back is in the direction of the loading table.
A41C 5/00 - Machines, appliances, or methods for manufacturing corsets or brassières
A41H 1/02 - Devices for taking measurements on the human body
A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
G01B 21/20 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring contours or curvatures, e.g. determining profile
An intranasal pharmaceutical powder composition comprising particles that comprise an active agent, a carrier, and at least one member which is a thickening agent, a pH adjusting agent, a sugar alcohol, or any combination thereof. The carrier comprises microcrystalline cellulose; about 20 percent by weight of the active agent in the particles is amorphous as determined by X-ray diffraction. When the active agent has a crystalline form, a solubility of the active agent in a crystalline form in an aqueous liquid ranges from about 0.1 pg/mL to about 1 mg/mL in water at a temperature of 37± 0.5 °C. The particles have an average particle size of from about 10 microns to about 300 microns, as measured by laser diffraction. When the intranasal pharmaceutical powder composition is administered, a pharmacokinetic parameter of the active agent improves by at least 15%.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/515 - Barbituric acidsDerivatives thereof, e.g. sodium pentobarbital
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
36.
OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent
To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Provided herein are vaccine compositions for example in a dry powder form for intranasal delivery, and their preparation methods. Also provided are methods of using vaccine compositions, for example in stimulating mucosal or systemic immune responses by delivering the vaccine compositions intranasally.
[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound.
4 (A)
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 279/16 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
C07D 277/48 - Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07C 323/60 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 277/26 - Radicals substituted by sulfur atoms
C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 307/71 - Nitro radicals attached in position 5
C07C 317/28 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
C07D 307/72 - Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2
To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. [Solution] This micro-encapsulated aquaculture feed includes. an oil phase 11 having an oil-soluble nutrient component; a water phase 13 which is present inside the oil phase 11, and which includes a water-soluble nutrient component; and a film 15 which includes the oil phase 11 and the water phase 13. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.
[Problem] To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. [Solution] This micro-encapsulated aquaculture feed includes: an oil phase 11 having an oil-soluble nutrient component; a water phase 13 which is present inside the oil phase 11, and which includes a water-soluble nutrient component; and a film 15 which includes the oil phase 11 and the water phase 13. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.
[Problem] To provide: a chiral nucleic acid adjuvant having an anti-allergic activity; and an anti-allergic agent. [Solution] An adjuvant which contains an oligonucleotide containing two to four CpG motifs and having a length of 14 to 32 nucleotides, wherein each of the CpG motifs is a sequence comprising 5'-X1CpGX2-3', and wherein a phosphorothioate-bound nucleic acid base is linked to the 3' side of each of at least two of the CpG motifs and each of the 5'-terminal and the 3'-terminal of the oligonucleotide is a phosphorothioate-bound S-type nucleic acid base, and wherein the oligonucleotide contains at least one base that is not modified with a phosphorothioate. An adjuvant containing an oligonucleotide represented by SEQ ID NO: 67. An anti-allergy agent comprising each of the adjuvants.
[Problem] To provide: a chiral nucleic acid adjuvant having an immunity induction activity; and an immunity induction activator. [Solution] An adjuvant which contains an oligonucleotide containing two to four CpG motifs and having a length of 14 to 32 nucleotides, wherein each of the CpG motifs is a sequence comprising 5'-X1CpGX2-3', and wherein a phosphorothioate (PS)-bound nucleic acid base is linked to the 3' side of each of at least two of the CpG motifs and each of the 5'-terminal and the 3'-terminal of the oligonucleotide is a PS-bound S-type nucleic acid base, and wherein the oligonucleotide contains at least one base that is not modified with a phosphorothioate. An immunity induction activator comprising the adjuvant.
[Problem] To provide a chiral nucleic acid adjuvant having an antitumor effect and an antitumor agent. [Solution] An adjuvant comprising an oligonucleotide consisting of 14-32 nucleotides and containing 2-4 CpG motifs, said CpG motifs being a sequence represented by 5'-X1CpGX2-3', wherein: a phosphorothioate (PS)-bonded nucleic acid base is connected to the 3' side of at least two CpG motifs, while PS-bonded S-form nucleic acid bases are located at the 5'- and 3'-ends; and the aforesaid oligonucleotide contains at least one base that is not PS-modified. An antitumor agent comprising the aforesaid adjuvant.
When a primate is t restrained by a movable partition wall, friction with vertical bars of a lattice of the partition wall causing damages on roots of limbs of the primate is alleviated to reduce or solve such damages. In a primate restraint device comprising a containing body having both side surfaces, a top surface and a bottom surface, a rear surface door capable of opening and shutting the rear surface side of the containing body, and a partition wall formed movably frontward and rearward in the containing body and capable of being fixed at a desired position in the containing body, some sites among vertical bar members of the partition wall, with which roots of limbs of the primate are brought into contact while the limbs are forced to protrude frontward and restrained, are covered with protective cylinders which are rotatable with respect to the vertical bar members.
Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.
Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound. [Solution] A compound represented by formula (A), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. R1-R2-R3-R4 (A)
C07C 323/60 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 277/20 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 277/26 - Radicals substituted by sulfur atoms
C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
48.
OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT
[Problem] To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. [Solution] This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices. Formulations and methods of manufacture are provided for dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations.
The purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-.alpha. (IFN.alpha.). Solution The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5'-X1X2CpGX3X4-3' (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non- methylated CpG residue having a phosphate skeleton modification, X1X2 represents any one of AA, AT, GA and GT, and X3X4 represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
[Problem] The purpose of the present invention is to provide: a stereoisomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-α (IFNα). [Solution] The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5'-X1X2CpGX3X4-3' (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, X1X2 represents any one of AA, AT, GA and GT, and X3X4 represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
When a primate is t restrained by a partition wall movable frontward and rearward in a restraint device, friction with vertical bars of a lattice of the partition wall causing damages on roots of limbs of the primate is alleviated in order to reduce or solve such damages. In a primate restraint device 10 comprising a containing body 20 having both side surfaces, a top surface and a bottom surface, a rear surface door 50 capable of opening and shutting the rear surface side of the containing body 20, and a partition wall 30 formed movably frontward and rearward in the containing body 20 and capable of being fixed at a desired position in the containing body 20, some sites among vertical bar members 31 of the partition wall 30, with which roots of limbs of the primate are brought into contact while the limbs are forced to protrude frontward and restrained, are covered with protective cylinders 33 which are rotatable with respect to the vertical bar members 31.
The present invention reduces or eliminates injuries such as those to the base of the limbs of a primate in a restrainer caused by friction with vertical bars in the grid of a barrier that is movable in a front-back direction, by reducing the friction when using the barrier to restrain the primate. A restrainer (10) for primates has: a storage body (20) having two side surfaces, a top surface, and a bottom surface; a rear surface door (50) which can open and close the rear surface side of the storage body (20); and a barrier (30) that is formed so as to be movable inside the storage body (20) in a front-back direction, and that is formed so as to be fixable at a desired position inside the storage body (20). Protective tubing (33) is rotatably inserted onto vertical bar members (31) of the barrier (30) at locations on the vertical bar members (31) where the base parts of the limbs of a primate would make contact when the limbs of the primate are extended in the frontal direction and restrained.
Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
Provided is a means with which it is possible to swiftly and safely carry out work on a monkey that was moved into a retention container from a home cage. This working platform (10) is provided with: a base (20) having a horizontal moving means (23); and a lattice surface (60) installed perpendicular to the base (20). A hook (71) disposed on a retention container (70) for temporarily storing a laboratory animal for the treatment thereof is formed in a suspendable manner on the lattice surface (60).
[Problem] To provide a peptide which can be produced and processed more readily compared with prothymosin α, which is conventionally known, or a peptide thereof and has an activity at a level equivalent to or higher than that of prothymosin α or a peptide thereof. [Solution] The present invention provides an ameliorating agent for blood-organ barrier dysfunction, a therapeutic agent for diseases associated with blood-organ barrier dysfunction or ischemic diseases or a nerve cell death inhibitor, each comprising, as an active ingredient, a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or a peptide having substantially the same function as that of the aforementioned peptide.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
57.
THERAPEUTIC AGENT FOR FIBROMYALGIA WHICH COMPRISES DONEPEZIL
[Problem] The purpose of the present invention is to provide a medicinal agent effective for the treatment of fibromyalgia. [Solution] The present invention relates to a therapeutic agent for fibromyalgia, which comprises an effective amount of donepezil or a pharmaceutically acceptable salt of donepezil as an active ingredient. Pain associated with fibromyalgia is not accompanied by any inflammation, and therefore there is not found any good amelioration method for the pain. Thus, the present invention provides a pain-ameliorating agent that is extremely effective for patients with the pain.
Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices. Formulations and methods of manufacture are provided for dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations.
Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices. Formulations and methods of manufacture are provided for dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations.
A primate restraint device capable of restricting the movement of a monkey and, particularly, capable of facilitating injection or blood collection. A primate restraint device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. The partition wall has provided therein hind-limb protrusion openings from which the hind limbs of the contained primate are caused to protrude to the outside.
A primate restraint device capable of restricting the movement of a monkey and, particularly, capable of facilitating transnasal intragastric administration or oral administration. A primate restraint device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. Both side surfaces are each formed by combining vertical bar members and horizontal bar members into a grid pattern, and at least some of the horizontal bar members of the side surface are curved downward to form chin support sections on which the chin of the contained primate is supported.
A01K 15/04 - Devices for impeding movementDevices for impeding passage through fencing
A01K 13/00 - Devices for grooming or caring of animals, e.g. curry-combsFetlock ringsTail-holdersDevices for preventing crib-bitingWashing devicesProtection against weather conditions or insects
A61D 3/00 - Appliances for supporting or fettering animals for operative purposes
A01K 1/06 - Devices for fastening animals, e.g. halters, toggles, neck-bars or chain fastenings
A01K 1/03 - Housing for domestic or laboratory animals
Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
Provided herein are methods for generating dry vaccine powder formulations comprising freeze-drying liquid formulations containing one or more antigens and one or more saccharides, to form a freeze-dried sample having an average particle diameter size of 5 to 100 µm without grinding. Such dry vaccine powder formulations are suitable for intranasal delivery.
Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
Formulations and methods of manufacture are provided for granisetron dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations. Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices.
A61M 15/08 - Inhaling devices inserted into the nose
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A primate retaining device capable of restraining the movement of a monkey and, particularly, capable of facilitating transnasal administration into the stomach or oral administration. A primate retaining device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. Both the side surfaces are each formed by combining vertical bar members and horizontal bar members into a grid pattern, and at least some of the horizontal bar members of the side surface are curved downward to form chin support sections on which the chin of the contained primate is supported.
A primate restraint device capable of restricting the movement of a monkey and, particularly, capable of facilitating injection or blood collection. A primate restraint device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. The partition wall has provided therein hind-limb protrusion openings from which the hind limbs of the contained primate are caused to protrude to the outside.
Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed.
A primate restraining device capable of restraining the movement of a monkey and, particularly, capable of facilitating injection or blood drawing. A primate restraining device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. The partition wall has provided therein hind-limb protrusion openings from which the hind limbs of the contained primate are caused to protrude to the outside.
A primate retaining device capable of restraining the movement of a monkey and, particularly, capable of facilitating transnasal administration into the stomach or oral administration. A primate retaining device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. Both the side surfaces are each formed by combining vertical bar members and horizontal bar members into a grid pattern, and at least some of the horizontal bar members of the side surface are curved downward to form chin support sections on which the chin of the contained primate is supported.
Formulations and methods of manufacture are provided for granisetron dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations. Devices for delivery of dry powder formulations are also provided. Devices can be single -use devices.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
73.
Test substance administration system for animal experiment
[Subject]
A test substance application system for animal experiment capable of administering a required amount of a test substance uniformly and reliably from a nose or a mouth into a nasal cavity or into a lung of an experimental animal is provided.
[Means for Solution]
The system includes a respiration monitoring device 2 that monitors a respiration state of an experimental animal detected by a respiration pick-up device 1 to thereby measure a timing upon switching from an expiratory phase to an inhalatory phase and outputs a trigger signal T at that timing, and an application device 3 that sprays a predetermined amount of a test substance into a nasal cavity or an oral cavity of the experimental animal when the trigger signal T is outputted from the device 2.
Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties; and a physiologically active substance.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.
Disclosed is a tool for analysis of the expression of a gene from a crab-eating monkey (Macaca fascicularis). The tool comprises a set of nucleic acid sequences each comprising a nucleotide sequence identical or substantially identical to each of at least two nucleotide sequences selected from the group consisting of the nucleotide sequences depicted in SEQ ID NOs:1-14 or a partial sequence thereof. Also disclosed is a method for analysis of the expression of a gene from a crab-eating monkey (Macaca fascicularis), which comprises determining a transcript of the gene in a sample derived from a crab-eating monkey by utilizing the tool.
Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
Improvement for the device to deliver the powdery medicine into nasal cavities in which a capsule setting/detaching part 40 is built drawably in the capsule housing/holding part 30, and cutting blades 60A, 60B are built in both axial ends of the capsule setting/detaching part 40 of the capsule housing/holding part 30 for cutting both axial ends of the capsule thereby perforating the capsule. A medicine capturing/collecting part 32 and a one-way valve 33 are built in a lower portion of the capsule housing/holding part 30, and a pump 50 having an air inlet valve 54 is built in the air flow inlet side thereof. A medicine delivery part 20 is built in the air exit of the capsule housing/holding part 30, a nozzle 22 is installed and medicine in the capsule can be dosed to the nasal cavities of the user by pressing the pump 50.
